Innate immunity merger raises €75m
Dutch Oxitope and Norwegian Arxx announced their merger to form Calluna Pharma Inc with the goal to develop therapies for inflammatory and fibrotic...
£26m for Cystic Fibrosis Drug Trial
With funding led by Panakes Partners and involvement from current investors, Enterprise Therapeutics Ltd. has received £26m (~€30.5m) for the Phase...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
Roche jumps ship on AC Immune
In recent trials, both Semorinemab, a monoclonal antibody (mAb) binding all forms of Tau, and Crenezumab, a mAb targeting multiple forms of misfolded...
Forbion participates in US financing rounds
Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
AMPLY Discovery Ltd bags £1.4m funding to tackle complex diseases
The 2021 spin-out from the Queen’s University Belfast announced it will close a seed financing round this year.vAMPLY is speeding up the discovery of...